

Randomized, controlled clinical trial of the DIALIVE liver dialysis device vs. STANDARD OF CARE in patients with acute-on-chronic liver failure




Multicenter Europe

ACLF 1-3a

>18-81 yr



Randomized clinical trial



INTENSIVE CARE UNIT



DYSFUNCTIONAL ALBUMIN



ALBUMIN REPLACEMENT

PAMPs

PATHOGEN-ASSOCIATED MOLECULAR PATTERNS

DAMPs

DAMAGE-ASSOCIATED MOLECULAR PATTERNS



DIALIVE

STANDARD OF CARE

DIALIVE is SAFE and has potential as a DISEASE MODIFYING THERAPY for patients with ACLF:

- Removes damaged albumin
- Improves albumin function
- Removes endotoxin
- Shortens the time to ACLF resolution
- Is likely to reduce 28-day mortality



Treatment of ACLF is an urgent unmet medical need